journal article·2023-02-09Open access

Drug-loaded microbubble delivery system to enhance PD-L1 blockade immunotherapy with remodeling immune microenvironment

Jun Zheng, Ju Huang, Liang Zhang, Mengna Wang, Lihong Xu, Xiaoyun Dou, Xiaojing Leng, Mingxiao Fang, Yang Sun, Zhigang Wang

Biomaterials Research· Volume 27· Issue 1

Abstract

Abstract Background Although programmed cell death protein 1 (PD-1)/ programmed cell death-ligand protein 1 (PD-L1) checkpoint blockade immunotherapy demonstrates great promise in cancer treatment, poor infiltration of T cells resulted from tumor immunosuppressive microenvironment (TIME) and insufficient accumulation of anti-PD-L1 (αPD-L1) in tumor sites diminish the immune response. Herein, we reported a drug-loaded microbubble delivery system to overcome these obstacles and enhance PD-L1 blockade immunotherapy. Methods Docetaxel (DTX) and imiquimod (R837)-loaded microbubbles (RD@MBs) were synthesized via a typical rotary evaporation method combined with mechanical oscillation. The targeted release of drugs was achieved by using the directional "bursting" capability of ultrasound-targeted microbubble destruction (UTMD) technology. The antitumor immune response by RD@MBs combining αPD-L1 were evaluated on 4T1 and CT26 tumor models. Results The dying tumor cells induced by DTX release tumor-associated antigens (TAAs), together with R837, promoted the activation, proliferation and recruitment of T cells. Besides, UTMD technology and DTX enhanced the accumulation of αPD-L1 in tumor sites. Moreover, RD@MBs remolded TIME, including the polarization of M2-phenotype tumor-associated macrophages (TAMs) to M1-phenotype, and reduction of myeloid-derived suppressor cells (MDSCs). The RD@MBs + αPD-L1 synergistic therapy not only effectively inhibited the growth of primary tumors, but also significantly inhibited the mimic distant tumors as well as lung metastases. Conclusion PD-L1 blockade immunotherapy was enhanced by RD@MBs delivery system.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Ultrasound and Hyperthermia Applications · Nanoplatforms for cancer theranostics · 3D Printing in Biomedical Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Ultrasound in Medicine and Engineering, Institute of Ultrasound Imaging, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, People’s Republic of China.

Ultrasound Department, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400042, People’s Republic of China.

Department of Pathology, College of Basic Medicine, Chongqing Medical University, Chongqing 400016, People’s Republic of China.

Institute of Life Sciences, Chongqing Medical University, Chongqing 400016, People’s Republic of China.

Funding

National Natural Science Foundation of China · Key Project of Application Development Plan of Chongqing · China Postdoctoral Science Foundation · Chongqing Graduate Research Innovation Project · Natural Science Foundation of Chongqing

References (52)

Show source-provided references
1. 10.1172/JCI8387110.1172/JCI83871 ↗
2. 10.1016/j.biomaterials.2021.12085610.1016/j.biomaterials.2021.120856 ↗
3. 10.1038/s41467-021-24604-910.1038/s41467-021-24604-9 ↗
4. 10.1002/adma.20200003810.1002/adma.202000038 ↗
5. 10.7150/thno.5839010.7150/thno.58390 ↗
6. 10.1038/s41467-022-31926-910.1038/s41467-022-31926-9 ↗
7. 10.1002/adma.20200757610.1002/adma.202007576 ↗
8. 10.1021/acsami.1c0463810.1021/acsami.1c04638 ↗
9. 10.1021/acsnano.5b0677910.1021/acsnano.5b06779 ↗
10. 10.1158/0008-5472.CAN-20-299010.1158/0008-5472.CAN-20-2990 ↗
11. 10.1136/jitc-2021-00259110.1136/jitc-2021-002591 ↗
12. 10.1158/1078-0432.CCR-06-219710.1158/1078-0432.CCR-06-2197 ↗
13. 10.1039/D0SC06557A10.1039/D0SC06557A ↗
14. 10.1016/j.actbio.2020.07.06310.1016/j.actbio.2020.07.063 ↗
15. 10.1039/D0NR04520A10.1039/D0NR04520A ↗
16. 10.1021/acs.nanolett.1c0020910.1021/acs.nanolett.1c00209 ↗
17. 10.1002/smll.20200354310.1002/smll.202003543 ↗
18. 10.1073/pnas.180328111510.1073/pnas.1803281115 ↗
19. 10.1016/j.apsb.2019.08.00310.1016/j.apsb.2019.08.003 ↗
20. 10.1002/smll.20200817710.1002/smll.202008177 ↗
21. 10.1186/s12951-021-00835-210.1186/s12951-021-00835-2 ↗
22. 10.1016/j.jconrel.2020.02.04410.1016/j.jconrel.2020.02.044 ↗
23. 10.1158/1078-0432.CCR-10-073310.1158/1078-0432.CCR-10-0733 ↗
24. 10.1126/sciadv.abb311610.1126/sciadv.abb3116 ↗
25. 10.1158/1078-0432.CCR-22-015910.1158/1078-0432.CCR-22-0159 ↗
26. 10.1016/j.addr.2008.03.00510.1016/j.addr.2008.03.005 ↗
27. 10.1158/1078-0432.CCR-16-314610.1158/1078-0432.CCR-16-3146 ↗
28. 10.1016/j.canlet.2019.08.00510.1016/j.canlet.2019.08.005 ↗
29. 10.1002/advs.20210204310.1002/advs.202102043 ↗
30. 10.1126/sciadv.aba077610.1126/sciadv.aba0776 ↗
31. 10.1016/j.biomaterials.2020.12054610.1016/j.biomaterials.2020.120546 ↗
32. 10.1038/s41467-019-11269-810.1038/s41467-019-11269-8 ↗
33. 10.1021/acsnano.9b0197910.1021/acsnano.9b01979 ↗
34. 10.1038/cr.2016.15710.1038/cr.2016.157 ↗
35. 10.1021/acsnano.5b0201410.1021/acsnano.5b02014 ↗
36. 10.1038/s41467-019-09760-310.1038/s41467-019-09760-3 ↗
37. 10.1021/acsnano.7b0071510.1021/acsnano.7b00715 ↗
38. 10.1016/j.biomaterials.2019.11951510.1016/j.biomaterials.2019.119515 ↗
39. 10.1038/s41590-021-00967-510.1038/s41590-021-00967-5 ↗
40. 10.1038/sj.bjc.660581410.1038/sj.bjc.6605814 ↗
41. 10.1016/j.jconrel.2019.09.02110.1016/j.jconrel.2019.09.021 ↗
42. 10.1016/S0140-6736(07)60781-810.1016/S0140-6736(07)60781-8 ↗
43. 10.1186/s12943-018-0864-310.1186/s12943-018-0864-3 ↗
44. 10.1002/advs.20200214710.1002/advs.202002147 ↗
45. 10.1016/j.jconrel.2020.01.05110.1016/j.jconrel.2020.01.051 ↗
46. 10.1038/nrclinonc.2018.2910.1038/nrclinonc.2018.29 ↗
47. 10.1038/s41416-020-01048-410.1038/s41416-020-01048-4 ↗
48. 10.1002/adma.20180222810.1002/adma.201802228 ↗
49. 10.1016/j.biomaterials.2020.12063610.1016/j.biomaterials.2020.120636 ↗
50. 10.7150/thno.4551110.7150/thno.45511 ↗
51. 10.1039/C9CS00648F10.1039/C9CS00648F ↗
52. 10.1002/advs.20190055710.1002/advs.201900557 ↗